LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 11

Search options

  1. Article ; Online: Web-Based Intervention Effects on Mild Cognitive Impairment Based on Apolipoprotein E Genotype: Quasi-Experimental Study.

    Tsolaki, Anthoula C / Tsolaki, Magda / Pandria, Niki / Lazarou, Eftychia / Gkatzima, Olymbia / Zilidou, Vasiliki / Karagianni, Maria / Iakovidou-Kritsi, Zafiroula / Kimiskidis, Vasilios K / Bamidis, Panagiotis D

    Journal of medical Internet research

    2020  Volume 22, Issue 5, Page(s) e14617

    Abstract: Background: Apolipoprotein E (APOE) ε4 allele is a major genetic risk factor for Alzheimer disease and mild cognitive impairment (MCI). Computer-based training programs can improve cognitive performance in elderly populations. However, the effects of ... ...

    Abstract Background: Apolipoprotein E (APOE) ε4 allele is a major genetic risk factor for Alzheimer disease and mild cognitive impairment (MCI). Computer-based training programs can improve cognitive performance in elderly populations. However, the effects of computer-based interventions on MCI APOE ε4 carriers have never been studied before.
    Objective: The effects of different web-based interventions and the APOE isoform-specific differences in training outcomes are investigated.
    Methods: Using a quasi-experimental study design, 202 participants with MCI aged 60 years and older took part in three different intervention programs (physical and cognitive [Long-Lasting Memories, or LLM], cognitive [Active Control, or AC], or physical intervention [Physical Training Control, or PTC]) via an innovative information and communication technologies exergaming platform. Participants in each interventional group were subdivided into APOE ε4 carriers and non-APOE ε4 carriers. All participants underwent an extensive neuropsychological evaluation before and after the training, blood tests, and brain imaging.
    Results: All interventions resulted in multiple statistically significant cognitive benefits after the intervention. Verbal learning (California Verbal Learning Test: immediate recall test score-LLM: P=.04; AC: P<.001), working memory (digit span forward and backward test scores-AC: P=.03; PTC: P=.02 and P=.006, respectively), and long-term memory (California Verbal Learning Test: delayed recall test score-LLM: P=.02; AC: P=.002; and PTC: P=.02) were improved. There was no statistically significant difference among the intervention effects. APOE ε4 presence moderates intervention effects as the LLM intervention improved only their task-switching processing speed (Trail Making Test, Part B: P=.03) and the PTC intervention improved only the working memory (digit span backward: P=.03). No significant performance alteration was noted for the APOE ε4+ cognitive AC training group.
    Conclusions: None of the applied interventions could be identified as the optimal one; it is suggested, however, that combined cognitive and physical training and physical training via exergaming may be more effective for the high-risk MCI ΑPOE ε4+ subgroup.
    MeSH term(s) Apolipoproteins E/genetics ; Cognitive Dysfunction/therapy ; Female ; Genotype ; Humans ; Internet-Based Intervention/statistics & numerical data ; Male ; Middle Aged ; Neuropsychological Tests/standards ; Non-Randomized Controlled Trials as Topic ; Risk Factors
    Chemical Substances Apolipoproteins E
    Language English
    Publishing date 2020-05-07
    Publishing country Canada
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2028830-X
    ISSN 1438-8871 ; 1439-4456
    ISSN (online) 1438-8871
    ISSN 1439-4456
    DOI 10.2196/14617
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?

    Travassos, Maria / Santana, Isabel / Baldeiras, Inês / Tsolaki, Magda / Gkatzima, Olymbia / Sermin, Genc / Yener, Görsev G / Simonsen, Anja / Hasselbalch, Steen G / Kapaki, Elisabeth / Mara, Bourbouli / Cunha, Rodrigo A / Agostinho, Paula / Blennow, Kaj / Zetterberg, Henrik / Mendes, Vera M / Manadas, Bruno / de Mendon, Alexandreça

    Journal of Alzheimer's disease : JAD

    2015  Volume 47, Issue 4, Page(s) 1069–1078

    Abstract: Caffeine may be protective against Alzheimer's disease (AD) by modulating amyloid-β (Aβ) metabolic pathways. The present work aimed to study a possible association of caffeine consumption with the cerebrospinal fluid (CSF) biomarkers, particularly Aβ. ... ...

    Abstract Caffeine may be protective against Alzheimer's disease (AD) by modulating amyloid-β (Aβ) metabolic pathways. The present work aimed to study a possible association of caffeine consumption with the cerebrospinal fluid (CSF) biomarkers, particularly Aβ. The study included 88 patients with AD or mild cognitive impairment. The consumption of caffeine and theobromine was evaluated using a validated food questionnaire. Quantification of caffeine and main active metabolites was performed with liquid chromatography coupled to tandem mass spectrometry. The levels of A(1-42), total tau, and phosphorylated tau in the CSF were determined using sandwich ELISA methods and other Aβ species, Aβ(X-38), Aβ(X-40), and Aβ(X-42), with the MSD Aβ Triplex assay. The concentration of caffeine was 0.79±1.15 μg/mL in the CSF and 1.20±1.88 μg/mL in the plasma. No correlation was found between caffeine consumption and Aβ42 in the CSF. However, a significant positive correlation was found between the concentrations of theobromine, both in the CSF and in the plasma, with Aβ42 in the CSF. Theobromine in the CSF was positively correlated with the levels of other xanthines in the CSF, but not in the plasma, suggesting that it may be formed by central metabolic pathways. In conclusion, caffeine consumption does not modify the levels of CSF biomarkers, and does not require to be controlled for when measuring CSF biomarkers in a clinical setting. Since theobromine is associated with a favorable Aβ profile in the CSF, the possibility that it might have a protective role in AD should be further investigated.
    MeSH term(s) Aged ; Aged, 80 and over ; Alzheimer Disease/blood ; Alzheimer Disease/cerebrospinal fluid ; Amyloid beta-Peptides/blood ; Amyloid beta-Peptides/cerebrospinal fluid ; Biomarkers/cerebrospinal fluid ; Caffeine/administration & dosage ; Caffeine/blood ; Caffeine/cerebrospinal fluid ; Diet ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Male ; Middle Aged ; Theobromine/blood ; Theobromine/cerebrospinal fluid ; tau Proteins/blood ; tau Proteins/cerebrospinal fluid
    Chemical Substances Amyloid beta-Peptides ; Biomarkers ; MAPT protein, human ; tau Proteins ; Caffeine (3G6A5W338E) ; Theobromine (OBD445WZ5P)
    Language English
    Publishing date 2015
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-150374
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.

    Ramos de Matos, Mafalda / Ferreira, Catarina / Herukka, Sanna-Kaisa / Soininen, Hilkka / Janeiro, André / Santana, Isabel / Baldeiras, Inês / Almeida, Maria Rosário / Lleó, Alberto / Dols-Icardo, Oriol / Alcolea, Daniel / Benussi, Luisa / Binetti, Giuliano / Paterlini, Anna / Ghidoni, Roberta / Nacmias, Benedetta / Meulenbroek, Olga / van Waalwijk van Doorn, Linda J C / Kuiperi, H Bea J /
    Hausner, Lucrezia / Waldemar, Gunhild / Simonsen, Anja Hviid / Tsolaki, Magda / Gkatzima, Olymbia / Resende de Oliveira, Catarina / Verbeek, Marcel M / Clarimon, Jordi / Hiltunen, Mikko / de Mendonça, Alexandre / Martins, Madalena

    Journal of Alzheimer's disease : JAD

    2018  Volume 66, Issue 2, Page(s) 639–652

    Abstract: Cerebrospinal fluid (CSF) biomarkers have been extensively investigated in the Alzheimer's disease (AD) field, and are now being applied in clinical practice. CSF amyloid-beta (Aβ1-42), total tau (t-tau), and phosphorylated tau (p-tau) reflect disease ... ...

    Abstract Cerebrospinal fluid (CSF) biomarkers have been extensively investigated in the Alzheimer's disease (AD) field, and are now being applied in clinical practice. CSF amyloid-beta (Aβ1-42), total tau (t-tau), and phosphorylated tau (p-tau) reflect disease pathology, and may be used as quantitative traits for genetic analyses, fostering the identification of new genetic factors and the proposal of novel biological pathways of the disease. In patients, the concentration of CSF Aβ1-42 is decreased due to the accumulation of Aβ1-42 in amyloid plaques in the brain, while t-tau and p-tau levels are increased, indicating the extent of neuronal damage. To better understand the biological mechanisms underlying the regulation of AD biomarkers, and its relation to AD, we examined the association between 36 selected single nucleotide polymorphisms (SNPs) and AD biomarkers Aβ1-42, t-tau, and p-tau in CSF in a cohort of 672 samples (571 AD patients and 101 controls) collected within 10 European consortium centers.Our results highlighted five genes, APOE, LOC100129500, PVRL2, SNAR-I, and TOMM40, previously described as main players in the regulation of CSF biomarkers levels, further reinforcing a role for these in AD pathogenesis. Three new AD susceptibility loci, INPP5D, CD2AP, and CASS4, showed specific association with CSF tau biomarkers. The identification of genes that specifically influence tau biomarkers point out to mechanisms, independent of amyloid processing, but in turn related to tau biology that may open new venues to be explored for AD treatment.
    MeSH term(s) Adaptor Proteins, Signal Transducing/genetics ; Aged ; Aged, 80 and over ; Alzheimer Disease/cerebrospinal fluid ; Alzheimer Disease/genetics ; Amyloid beta-Peptides/cerebrospinal fluid ; Apolipoproteins E/genetics ; Biomarkers/cerebrospinal fluid ; Cytoskeletal Proteins/genetics ; Female ; Genetic Variation/genetics ; Genotype ; Humans ; Male ; Middle Aged ; Peptide Fragments/cerebrospinal fluid ; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases/genetics ; Phosphorylation/genetics ; Quantitative Trait Loci ; tau Proteins/cerebrospinal fluid
    Chemical Substances Adaptor Proteins, Signal Transducing ; Amyloid beta-Peptides ; Apolipoproteins E ; Biomarkers ; CASS4 protein, human ; CD2-associated protein ; Cytoskeletal Proteins ; Peptide Fragments ; amyloid beta-protein (1-42) ; tau Proteins ; INPP5D protein, human (EC 3.1.3.86) ; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases (EC 3.1.3.86)
    Language English
    Publishing date 2018-10-12
    Publishing country Netherlands
    Document type Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-180512
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.

    Lelental, Natalia / Brandner, Sebastian / Kofanova, Olga / Blennow, Kaj / Zetterberg, Henrik / Andreasson, Ulf / Engelborghs, Sebastiaan / Mroczko, Barbara / Gabryelewicz, Tomasz / Teunissen, Charlotte / Mollenhauer, Brit / Parnetti, Lucilla / Chiasserini, Davide / Molinuevo, Jose Luis / Perret-Liaudet, Armand / Verbeek, Marcel M / Andreasen, Niels / Brosseron, Frederic / Bahl, Justyna M C /
    Herukka, Sanna-Kaisa / Hausner, Lucrezia / Frölich, Lutz / Labonte, Anne / Poirier, Judes / Miller, Anne-Marie / Zilka, Norbert / Kovacech, Branislav / Urbani, Andrea / Suardi, Silvia / Oliveira, Catarina / Baldeiras, Ines / Dubois, Bruno / Rot, Uros / Lehmann, Sylvain / Skinningsrud, Anders / Betsou, Fay / Wiltfang, Jens / Gkatzima, Olymbia / Winblad, Bengt / Buchfelder, Michael / Kornhuber, Johannes / Lewczuk, Piotr

    Journal of Alzheimer's disease : JAD

    2016  Volume 52, Issue 1, Page(s) 51–64

    Abstract: Background: Assay-vendor independent quality control (QC) samples for neurochemical dementia diagnostics (NDD) biomarkers are so far commercially unavailable. This requires that NDD laboratories prepare their own QC samples, for example by pooling ... ...

    Abstract Background: Assay-vendor independent quality control (QC) samples for neurochemical dementia diagnostics (NDD) biomarkers are so far commercially unavailable. This requires that NDD laboratories prepare their own QC samples, for example by pooling leftover cerebrospinal fluid (CSF) samples.
    Objective: To prepare and test alternative matrices for QC samples that could facilitate intra- and inter-laboratory QC of the NDD biomarkers.
    Methods: Three matrices were validated in this study: (A) human pooled CSF, (B) Aβ peptides spiked into human prediluted plasma, and (C) Aβ peptides spiked into solution of bovine serum albumin in phosphate-buffered saline. All matrices were tested also after supplementation with an antibacterial agent (sodium azide). We analyzed short- and long-term stability of the biomarkers with ELISA and chemiluminescence (Fujirebio Europe, MSD, IBL International), and performed an inter-laboratory variability study.
    Results: NDD biomarkers turned out to be stable in almost all samples stored at the tested conditions for up to 14 days as well as in samples stored deep-frozen (at - 80°C) for up to one year. Sodium azide did not influence biomarker stability. Inter-center variability of the samples sent at room temperature (pooled CSF, freeze-dried CSF, and four artificial matrices) was comparable to the results obtained on deep-frozen samples in other large-scale projects.
    Conclusion: Our results suggest that it is possible to replace self-made, CSF-based QC samples with large-scale volumes of QC materials prepared with artificial peptides and matrices. This would greatly facilitate intra- and inter-laboratory QC schedules for NDD measurements.
    MeSH term(s) Amyloid beta-Peptides/blood ; Amyloid beta-Peptides/cerebrospinal fluid ; Animals ; Anti-Bacterial Agents/pharmacology ; Biomarkers/blood ; Biomarkers/cerebrospinal fluid ; Cattle ; Clinical Chemistry Tests/standards ; Dementia/blood ; Dementia/cerebrospinal fluid ; Humans ; Peptide Fragments/blood ; Peptide Fragments/cerebrospinal fluid ; Quality Control ; Reference Standards ; Serum Albumin, Bovine/analysis ; Sodium Azide/pharmacology ; Time Factors ; Tissue Preservation/methods ; tau Proteins/blood ; tau Proteins/cerebrospinal fluid
    Chemical Substances Amyloid beta-Peptides ; Anti-Bacterial Agents ; Biomarkers ; MAPT protein, human ; Peptide Fragments ; amyloid beta-protein (1-40) ; amyloid beta-protein (1-42) ; tau Proteins ; Serum Albumin, Bovine (27432CM55Q) ; Sodium Azide (968JJ8C9DV)
    Language English
    Publishing date 2016--01
    Publishing country Netherlands
    Document type Comparative Study ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't ; Validation Studies
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-150883
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.

    Jansen, Willemijn J / Janssen, Olin / Tijms, Betty M / Vos, Stephanie J B / Ossenkoppele, Rik / Visser, Pieter Jelle / Aarsland, Dag / Alcolea, Daniel / Altomare, Daniele / von Arnim, Christine / Baiardi, Simone / Baldeiras, Ines / Barthel, Henryk / Bateman, Randall J / Van Berckel, Bart / Binette, Alexa Pichet / Blennow, Kaj / Boada, Merce / Boecker, Henning /
    Bottlaender, Michel / den Braber, Anouk / Brooks, David J / Van Buchem, Mark A / Camus, Vincent / Carill, Jose Manuel / Cerman, Jiri / Chen, Kewei / Chételat, Gaël / Chipi, Elena / Cohen, Ann D / Daniels, Alisha / Delarue, Marion / Didic, Mira / Drzezga, Alexander / Dubois, Bruno / Eckerström, Marie / Ekblad, Laura L / Engelborghs, Sebastiaan / Epelbaum, Stéphane / Fagan, Anne M / Fan, Yong / Fladby, Tormod / Fleisher, Adam S / Van der Flier, Wiesje M / Förster, Stefan / Fortea, Juan / Frederiksen, Kristian Steen / Freund-Levi, Yvonne / Frings, Lars / Frisoni, Giovanni B / Fröhlich, Lutz / Gabryelewicz, Tomasz / Gertz, Hermann-Josef / Gill, Kiran Dip / Gkatzima, Olymbia / Gómez-Tortosa, Estrella / Grimmer, Timo / Guedj, Eric / Habeck, Christian G / Hampel, Harald / Handels, Ron / Hansson, Oskar / Hausner, Lucrezia / Hellwig, Sabine / Heneka, Michael T / Herukka, Sanna-Kaisa / Hildebrandt, Helmut / Hodges, John / Hort, Jakub / Huang, Chin-Chang / Iriondo, Ane Juaristi / Itoh, Yoshiaki / Ivanoiu, Adrian / Jagust, William J / Jessen, Frank / Johannsen, Peter / Johnson, Keith A / Kandimalla, Ramesh / Kapaki, Elisabeth N / Kern, Silke / Kilander, Lena / Klimkowicz-Mrowiec, Aleksandra / Klunk, William E / Koglin, Norman / Kornhuber, Johannes / Kramberger, Milica G / Kuo, Hung-Chou / Van Laere, Koen / Landau, Susan M / Landeau, Brigitte / Lee, Dong Young / de Leon, Mony / Leyton, Cristian E / Lin, Kun-Ju / Lleó, Alberto / Löwenmark, Malin / Madsen, Karine / Maier, Wolfgang / Marcusson, Jan / Marquié, Marta / Martinez-Lage, Pablo / Maserejian, Nancy / Mattsson, Niklas / de Mendonça, Alexandre / Meyer, Philipp T / Miller, Bruce L / Minatani, Shinobu / Mintun, Mark A / Mok, Vincent C T / Molinuevo, Jose Luis / Morbelli, Silvia Daniela / Morris, John C / Mroczko, Barbara / Na, Duk L / Newberg, Andrew / Nobili, Flavio / Nordberg, Agneta / Olde Rikkert, Marcel G M / de Oliveira, Catarina Resende / Olivieri, Pauline / Orellana, Adela / Paraskevas, George / Parchi, Piero / Pardini, Matteo / Parnetti, Lucilla / Peters, Oliver / Poirier, Judes / Popp, Julius / Prabhakar, Sudesh / Rabinovici, Gil D / Ramakers, Inez H / Rami, Lorena / Reiman, Eric M / Rinne, Juha O / Rodrigue, Karen M / Rodríguez-Rodriguez, Eloy / Roe, Catherine M / Rosa-Neto, Pedro / Rosen, Howard J / Rot, Uros / Rowe, Christopher C / Rüther, Eckart / Ruiz, Agustín / Sabri, Osama / Sakhardande, Jayant / Sánchez-Juan, Pascual / Sando, Sigrid Botne / Santana, Isabel / Sarazin, Marie / Scheltens, Philip / Schröder, Johannes / Selnes, Per / Seo, Sang Won / Silva, Dina / Skoog, Ingmar / Snyder, Peter J / Soininen, Hilkka / Sollberger, Marc / Sperling, Reisa A / Spiru, Luisa / Stern, Yaakov / Stomrud, Erik / Takeda, Akitoshi / Teichmann, Marc / Teunissen, Charlotte E / Thompson, Louisa I / Tomassen, Jori / Tsolaki, Magda / Vandenberghe, Rik / Verbeek, Marcel M / Verhey, Frans R J / Villemagne, Victor / Villeneuve, Sylvia / Vogelgsang, Jonathan / Waldemar, Gunhild / Wallin, Anders / Wallin, Åsa K / Wiltfang, Jens / Wolk, David A / Yen, Tzu-Chen / Zboch, Marzena / Zetterberg, Henrik

    JAMA neurology

    2022  Volume 79, Issue 3, Page(s) 228–243

    Abstract: Importance: One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans. Prevalence estimates of ... ...

    Abstract Importance: One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans. Prevalence estimates of amyloid pathology are important for health care planning and clinical trial design.
    Objective: To estimate the prevalence of amyloid abnormality in persons with normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia and to examine the potential implications of cutoff methods, biomarker modality (CSF or PET), age, sex, APOE genotype, educational level, geographical region, and dementia severity for these estimates.
    Design, setting, and participants: This cross-sectional, individual-participant pooled study included participants from 85 Amyloid Biomarker Study cohorts. Data collection was performed from January 1, 2013, to December 31, 2020. Participants had normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia. Normal cognition and subjective cognitive decline were defined by normal scores on cognitive tests, with the presence of cognitive complaints defining subjective cognitive decline. Mild cognitive impairment and clinical AD dementia were diagnosed according to published criteria.
    Exposures: Alzheimer disease biomarkers detected on PET or in CSF.
    Main outcomes and measures: Amyloid measurements were dichotomized as normal or abnormal using cohort-provided cutoffs for CSF or PET or by visual reading for PET. Adjusted data-driven cutoffs for abnormal amyloid were calculated using gaussian mixture modeling. Prevalence of amyloid abnormality was estimated according to age, sex, cognitive status, biomarker modality, APOE carrier status, educational level, geographical location, and dementia severity using generalized estimating equations.
    Results: Among the 19 097 participants (mean [SD] age, 69.1 [9.8] years; 10 148 women [53.1%]) included, 10 139 (53.1%) underwent an amyloid PET scan and 8958 (46.9%) had an amyloid CSF measurement. Using cohort-provided cutoffs, amyloid abnormality prevalences were similar to 2015 estimates for individuals without dementia and were similar across PET- and CSF-based estimates (24%; 95% CI, 21%-28%) in participants with normal cognition, 27% (95% CI, 21%-33%) in participants with subjective cognitive decline, and 51% (95% CI, 46%-56%) in participants with mild cognitive impairment, whereas for clinical AD dementia the estimates were higher for PET than CSF (87% vs 79%; mean difference, 8%; 95% CI, 0%-16%; P = .04). Gaussian mixture modeling-based cutoffs for amyloid measures on PET scans were similar to cohort-provided cutoffs and were not adjusted. Adjusted CSF cutoffs resulted in a 10% higher amyloid abnormality prevalence than PET-based estimates in persons with normal cognition (mean difference, 9%; 95% CI, 3%-15%; P = .004), subjective cognitive decline (9%; 95% CI, 3%-15%; P = .005), and mild cognitive impairment (10%; 95% CI, 3%-17%; P = .004), whereas the estimates were comparable in persons with clinical AD dementia (mean difference, 4%; 95% CI, -2% to 9%; P = .18).
    Conclusions and relevance: This study found that CSF-based estimates using adjusted data-driven cutoffs were up to 10% higher than PET-based estimates in people without dementia, whereas the results were similar among people with dementia. This finding suggests that preclinical and prodromal AD may be more prevalent than previously estimated, which has important implications for clinical trial recruitment strategies and health care planning policies.
    MeSH term(s) Aged ; Alzheimer Disease/cerebrospinal fluid ; Alzheimer Disease/diagnostic imaging ; Alzheimer Disease/epidemiology ; Amyloid beta-Peptides/cerebrospinal fluid ; Amyloidogenic Proteins ; Amyloidosis ; Apolipoproteins E/genetics ; Biomarkers/cerebrospinal fluid ; Cognitive Dysfunction/diagnostic imaging ; Cognitive Dysfunction/epidemiology ; Cross-Sectional Studies ; Female ; Humans ; Male ; Middle Aged ; Peptide Fragments/cerebrospinal fluid ; Positron-Emission Tomography ; Prevalence ; tau Proteins/cerebrospinal fluid
    Chemical Substances Amyloid beta-Peptides ; Amyloidogenic Proteins ; Apolipoproteins E ; Biomarkers ; Peptide Fragments ; tau Proteins
    Language English
    Publishing date 2022-01-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2702023-X
    ISSN 2168-6157 ; 2168-6149
    ISSN (online) 2168-6157
    ISSN 2168-6149
    DOI 10.1001/jamaneurol.2021.5216
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study.

    Kruse, Niels / Persson, Staffan / Alcolea, Daniel / Bahl, Justyna M C / Baldeiras, Ines / Capello, Elisabetta / Chiasserini, Davide / Bocchio Chiavetto, Luisella / Emersic, Andreja / Engelborghs, Sebastiaan / Eren, Erden / Fladby, Tormod / Frisoni, Giovanni / García-Ayllón, María-Salud / Genc, Sermin / Gkatzima, Olymbia / Heegaard, Niels H H / Janeiro, André M / Kováčech, Branislav /
    Kuiperij, H Bea / Leitão, Maria J / Lleó, Alberto / Martins, Madalena / Matos, Mafalda / Mollergard, Hanne M / Nobili, Flavio / Öhrfelt, Annika / Parnetti, Lucilla / de Oliveira, Catarina Resende / Rot, Uros / Sáez-Valero, Javier / Struyfs, Hanne / Tanassi, Julia T / Taylor, Peggy / Tsolaki, Magda / Vanmechelen, Eugeen / Verbeek, Marcel M / Zilka, Norbert / Blennow, Kaj / Zetterberg, Henrik / Mollenhauer, Brit

    Neurobiology of aging

    2015  Volume 36, Issue 9, Page(s) 2587–2596

    Abstract: Decreased levels of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) in Parkinson's disease and related synucleinopathies have been reported, however, not consistently in all cross-sectional studies. To test the performance of one recently released ... ...

    Abstract Decreased levels of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) in Parkinson's disease and related synucleinopathies have been reported, however, not consistently in all cross-sectional studies. To test the performance of one recently released human-specific enzyme-linked immunosorbent assay (ELISA) for the quantification of aSyn in CSF, we carried out a round robin trial with 18 participating laboratories trained in CSF ELISA analyses within the BIOMARKAPD project in the EU Joint Program - Neurodegenerative Disease Research. CSF samples (homogeneous aliquots from pools) and ELISA kits (one lot) were provided centrally and data reported back to one laboratory for data analysis. Our study showed that although factors such as preanalytical sample handling and lot-to-lot variability were minimized by our study design, we identified high variation in absolute values of CSF aSyn even when the same samples and same lots of assays were applied. We further demonstrate that although absolute concentrations differ between laboratories the quantitative results are comparable. With further standardization this assay may become an attractive tool for comparing aSyn measurements in diverse settings. Recommendations for further validation experiments and improvement of the interlaboratory results obtained are given.
    MeSH term(s) Biomarkers/cerebrospinal fluid ; Enzyme-Linked Immunosorbent Assay ; Europe ; Female ; Humans ; International Cooperation ; Male ; Neurodegenerative Diseases/cerebrospinal fluid ; Parkinson Disease/cerebrospinal fluid ; Reproducibility of Results ; United States ; alpha-Synuclein/cerebrospinal fluid
    Chemical Substances Biomarkers ; alpha-Synuclein
    Language English
    Publishing date 2015-09
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 604505-4
    ISSN 1558-1497 ; 0197-4580
    ISSN (online) 1558-1497
    ISSN 0197-4580
    DOI 10.1016/j.neurobiolaging.2015.05.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

    Mattsson, Niklas / Groot, Colin / Jansen, Willemijn J / Landau, Susan M / Villemagne, Victor L / Engelborghs, Sebastiaan / Mintun, Mark M / Lleo, Alberto / Molinuevo, José Luis / Jagust, William J / Frisoni, Giovanni B / Ivanoiu, Adrian / Chételat, Gaël / Resende de Oliveira, Catarina / Rodrigue, Karen M / Kornhuber, Johannes / Wallin, Anders / Klimkowicz-Mrowiec, Aleksandra / Kandimalla, Ramesh /
    Popp, Julius / Aalten, Pauline P / Aarsland, Dag / Alcolea, Daniel / Almdahl, Ina S / Baldeiras, Inês / van Buchem, Mark A / Cavedo, Enrica / Chen, Kewei / Cohen, Ann D / Förster, Stefan / Fortea, Juan / Frederiksen, Kristian S / Freund-Levi, Yvonne / Gill, Kiran Dip / Gkatzima, Olymbia / Grimmer, Timo / Hampel, Harald / Herukka, Sanna-Kaisa / Johannsen, Peter / van Laere, Koen / de Leon, Mony J / Maier, Wolfgang / Marcusson, Jan / Meulenbroek, Olga / Møllergård, Hanne M / Morris, John C / Mroczko, Barbara / Nordlund, Arto / Prabhakar, Sudesh / Peters, Oliver / Rami, Lorena / Rodríguez-Rodríguez, Eloy / Roe, Catherine M / Rüther, Eckart / Santana, Isabel / Schröder, Johannes / Seo, Sang W / Soininen, Hilkka / Spiru, Luiza / Stomrud, Erik / Struyfs, Hanne / Teunissen, Charlotte E / Verhey, Frans R J / Vos, Stephanie J B / van Waalwijk van Doorn, Linda J C / Waldemar, Gunhild / Wallin, Åsa K / Wiltfang, Jens / Vandenberghe, Rik / Brooks, David J / Fladby, Tormod / Rowe, Christopher C / Drzezga, Alexander / Verbeek, Marcel M / Sarazin, Marie / Wolk, David A / Fleisher, Adam S / Klunk, William E / Na, Duk L / Sánchez-Juan, Pascual / Lee, Dong Young / Nordberg, Agneta / Tsolaki, Magda / Camus, Vincent / Rinne, Juha O / Fagan, Anne M / Zetterberg, Henrik / Blennow, Kaj / Rabinovici, Gil D / Hansson, Oskar / van Berckel, Bart N M / van der Flier, Wiesje M / Scheltens, Philip / Visser, Pieter Jelle / Ossenkoppele, Rik

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2018  Volume 14, Issue 7, Page(s) 913–924

    Abstract: Introduction: Apolipoprotein E (APOE) ε4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid β (Aβ) pathology.: Methods: We included 3451 ... ...

    Abstract Introduction: Apolipoprotein E (APOE) ε4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid β (Aβ) pathology.
    Methods: We included 3451 Aβ+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE ε4 prevalence in relation to age, sex, education, and geographical location.
    Results: The APOE ε4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in Aβ+ cognitively normal and Aβ+ mild cognitive impairment (P < .05) but not in Aβ+ AD dementia (P = .66). The prevalence was highest in Northern Europe but did not vary by sex or education.
    Discussion: The APOE ε4 prevalence in AD was higher than that in previous studies, which did not require presence of Aβ pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location.
    MeSH term(s) Aged ; Alleles ; Alzheimer Disease/metabolism ; Amyloid beta-Peptides/metabolism ; Apolipoprotein E4/genetics ; Biomarkers/cerebrospinal fluid ; Cognitive Dysfunction/metabolism ; Europe ; Female ; Humans ; Male ; Positron-Emission Tomography ; Prevalence
    Chemical Substances Amyloid beta-Peptides ; Apolipoprotein E4 ; Biomarkers
    Language English
    Publishing date 2018-03-28
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1016/j.jalz.2018.02.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.

    Jansen, Willemijn J / Ossenkoppele, Rik / Tijms, Betty M / Fagan, Anne M / Hansson, Oskar / Klunk, William E / van der Flier, Wiesje M / Villemagne, Victor L / Frisoni, Giovanni B / Fleisher, Adam S / Lleó, Alberto / Mintun, Mark A / Wallin, Anders / Engelborghs, Sebastiaan / Na, Duk L / Chételat, Gäel / Molinuevo, José Luis / Landau, Susan M / Mattsson, Niklas /
    Kornhuber, Johannes / Sabri, Osama / Rowe, Christopher C / Parnetti, Lucilla / Popp, Julius / Fladby, Tormod / Jagust, William J / Aalten, Pauline / Lee, Dong Young / Vandenberghe, Rik / Resende de Oliveira, Catarina / Kapaki, Elisabeth / Froelich, Lutz / Ivanoiu, Adrian / Gabryelewicz, Tomasz / Verbeek, Marcel M / Sanchez-Juan, Páscual / Hildebrandt, Helmut / Camus, Vincent / Zboch, Marzena / Brooks, David J / Drzezga, Alexander / Rinne, Juha O / Newberg, Andrew / de Mendonça, Alexandre / Sarazin, Marie / Rabinovici, Gil D / Madsen, Karine / Kramberger, Milica G / Nordberg, Agneta / Mok, Vincent / Mroczko, Barbara / Wolk, David A / Meyer, Philipp T / Tsolaki, Magda / Scheltens, Philip / Verhey, Frans R J / Visser, Pieter Jelle / Aarsland, Dag / Alcolea, Daniel / Alexander, Myriam / Almdahl, Ina S / Arnold, Steven E / Baldeiras, Inês / Barthel, Henryk / van Berckel, Bart N M / Blennow, Kaj / van Buchem, Mark A / Cavedo, Enrica / Chen, Kewei / Chipi, Elena / Cohen, Ann D / Förster, Stefan / Fortea, Juan / Frederiksen, Kristian S / Freund-Levi, Yvonne / Gkatzima, Olymbia / Gordon, Mark Forrest / Grimmer, Timo / Hampel, Harald / Hausner, Lucrezia / Hellwig, Sabine / Herukka, Sanna-Kaisa / Johannsen, Peter / Klimkowicz-Mrowiec, Aleksandra / Köhler, Sebastian / Koglin, Norman / van Laere, Koen / de Leon, Mony / Lisetti, Viviana / Maier, Wolfgang / Marcusson, Jan / Meulenbroek, Olga / Møllergård, Hanne M / Morris, John C / Nordlund, Arto / Novak, Gerald P / Paraskevas, George P / Perera, Gayan / Peters, Oliver / Ramakers, Inez H G B / Rami, Lorena / Rodríguez-Rodríguez, Eloy / Roe, Catherine M / Rot, Uros / Rüther, Eckart / Santana, Isabel / Schröder, Johannes / Seo, Sang W / Soininen, Hilkka / Spiru, Luiza / Stomrud, Erik / Struyfs, Hanne / Teunissen, Charlotte E / Vos, Stephanie J B / van Waalwijk van Doorn, Linda J C / Waldemar, Gunhild / Wallin, Åsa K / Wiltfang, Jens / Zetterberg, Henrik

    JAMA psychiatry

    2017  Volume 75, Issue 1, Page(s) 84–95

    Abstract: Importance: Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the ... ...

    Abstract Importance: Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials.
    Objective: To investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia.
    Design, setting, and participants: This cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017.
    Main outcomes and measures: Global cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score ≤27 or memory z score≤-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype.
    Results: Among 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4% [95% CI, 0%-7%] at 72 years and 21% [95% CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3% [95% CI, -1% to 6%], P = .16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16% [95% CI, 12%-20%], P < .001) and low MMSE (mean difference, 14% [95% CI, 12%-17%], P < .001) scores, and this association decreased with age. Low cognitive scores had limited utility for screening of amyloid positivity in persons with normal cognition and those with MCI. In persons with normal cognition, the age-related increase in low memory score paralleled the age-related increase in amyloid positivity with an intervening period of 10 to 15 years.
    Conclusions and relevance: Although low memory scores are an early marker of amyloid positivity, their value as a screening measure for early AD among persons without dementia is limited.
    MeSH term(s) Aged ; Alzheimer Disease/diagnosis ; Alzheimer Disease/physiopathology ; Alzheimer Disease/psychology ; Amyloid beta-Peptides/cerebrospinal fluid ; Brain/physiopathology ; Cognition Disorders/diagnosis ; Cognition Disorders/physiopathology ; Cognition Disorders/psychology ; Cognitive Dysfunction/diagnosis ; Cognitive Dysfunction/physiopathology ; Cognitive Dysfunction/psychology ; Cross-Sectional Studies ; Female ; Humans ; Male ; Memory, Episodic ; Mental Status and Dementia Tests ; Middle Aged ; Positron-Emission Tomography ; Reference Values
    Chemical Substances Amyloid beta-Peptides
    Language English
    Publishing date 2017-12-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2701203-7
    ISSN 2168-6238 ; 2168-622X
    ISSN (online) 2168-6238
    ISSN 2168-622X
    DOI 10.1001/jamapsychiatry.2017.3391
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

    Jansen, Willemijn J / Ossenkoppele, Rik / Knol, Dirk L / Tijms, Betty M / Scheltens, Philip / Verhey, Frans R J / Visser, Pieter Jelle / Aalten, Pauline / Aarsland, Dag / Alcolea, Daniel / Alexander, Myriam / Almdahl, Ina S / Arnold, Steven E / Baldeiras, Inês / Barthel, Henryk / van Berckel, Bart N M / Bibeau, Kristen / Blennow, Kaj / Brooks, David J /
    van Buchem, Mark A / Camus, Vincent / Cavedo, Enrica / Chen, Kewei / Chetelat, Gael / Cohen, Ann D / Drzezga, Alexander / Engelborghs, Sebastiaan / Fagan, Anne M / Fladby, Tormod / Fleisher, Adam S / van der Flier, Wiesje M / Ford, Lisa / Förster, Stefan / Fortea, Juan / Foskett, Nadia / Frederiksen, Kristian S / Freund-Levi, Yvonne / Frisoni, Giovanni B / Froelich, Lutz / Gabryelewicz, Tomasz / Gill, Kiran Dip / Gkatzima, Olymbia / Gómez-Tortosa, Estrella / Gordon, Mark Forrest / Grimmer, Timo / Hampel, Harald / Hausner, Lucrezia / Hellwig, Sabine / Herukka, Sanna-Kaisa / Hildebrandt, Helmut / Ishihara, Lianna / Ivanoiu, Adrian / Jagust, William J / Johannsen, Peter / Kandimalla, Ramesh / Kapaki, Elisabeth / Klimkowicz-Mrowiec, Aleksandra / Klunk, William E / Köhler, Sebastian / Koglin, Norman / Kornhuber, Johannes / Kramberger, Milica G / Van Laere, Koen / Landau, Susan M / Lee, Dong Young / de Leon, Mony / Lisetti, Viviana / Lleó, Alberto / Madsen, Karine / Maier, Wolfgang / Marcusson, Jan / Mattsson, Niklas / de Mendonça, Alexandre / Meulenbroek, Olga / Meyer, Philipp T / Mintun, Mark A / Mok, Vincent / Molinuevo, José Luis / Møllergård, Hanne M / Morris, John C / Mroczko, Barbara / Van der Mussele, Stefan / Na, Duk L / Newberg, Andrew / Nordberg, Agneta / Nordlund, Arto / Novak, Gerald P / Paraskevas, George P / Parnetti, Lucilla / Perera, Gayan / Peters, Oliver / Popp, Julius / Prabhakar, Sudesh / Rabinovici, Gil D / Ramakers, Inez H G B / Rami, Lorena / Resende de Oliveira, Catarina / Rinne, Juha O / Rodrigue, Karen M / Rodríguez-Rodríguez, Eloy / Roe, Catherine M / Rot, Uros / Rowe, Christopher C / Rüther, Eckart / Sabri, Osama / Sanchez-Juan, Páscual / Santana, Isabel / Sarazin, Marie / Schröder, Johannes / Schütte, Christin / Seo, Sang W / Soetewey, Femke / Soininen, Hilkka / Spiru, Luiza / Struyfs, Hanne / Teunissen, Charlotte E / Tsolaki, Magda / Vandenberghe, Rik / Verbeek, Marcel M / Villemagne, Victor L / Vos, Stephanie J B / van Waalwijk van Doorn, Linda J C / Waldemar, Gunhild / Wallin, Anders / Wallin, Åsa K / Wiltfang, Jens / Wolk, David A / Zboch, Marzena / Zetterberg, Henrik

    JAMA

    2015  Volume 313, Issue 19, Page(s) 1924–1938

    Abstract: Importance: Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the ... ...

    Abstract Importance: Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies.
    Objective: To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI).
    Data sources: Relevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators.
    Study selection: Studies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity.
    Data extraction and synthesis: Individual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies.
    Main outcomes and measures: Prevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations.
    Results: The prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-ε4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers, and 95 years for ε2ε3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality.
    Conclusions and relevance: Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia.
    MeSH term(s) Adult ; Age Factors ; Aged ; Aged, 80 and over ; Amyloid beta-Peptides/analysis ; Apolipoprotein E4/genetics ; Biomarkers/analysis ; Brain/pathology ; Cerebrospinal Fluid/chemistry ; Cognitive Dysfunction/pathology ; Dementia/pathology ; Female ; Genotype ; Humans ; Male ; Middle Aged ; Positron-Emission Tomography ; Prevalence ; Risk Factors
    Chemical Substances Amyloid beta-Peptides ; Apolipoprotein E4 ; Biomarkers
    Language English
    Publishing date 2015-05-19
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2015.4668
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.

    Kunkle, Brian W / Grenier-Boley, Benjamin / Sims, Rebecca / Bis, Joshua C / Damotte, Vincent / Naj, Adam C / Boland, Anne / Vronskaya, Maria / van der Lee, Sven J / Amlie-Wolf, Alexandre / Bellenguez, Céline / Frizatti, Aura / Chouraki, Vincent / Martin, Eden R / Sleegers, Kristel / Badarinarayan, Nandini / Jakobsdottir, Johanna / Hamilton-Nelson, Kara L / Moreno-Grau, Sonia /
    Olaso, Robert / Raybould, Rachel / Chen, Yuning / Kuzma, Amanda B / Hiltunen, Mikko / Morgan, Taniesha / Ahmad, Shahzad / Vardarajan, Badri N / Epelbaum, Jacques / Hoffmann, Per / Boada, Merce / Beecham, Gary W / Garnier, Jean-Guillaume / Harold, Denise / Fitzpatrick, Annette L / Valladares, Otto / Moutet, Marie-Laure / Gerrish, Amy / Smith, Albert V / Qu, Liming / Bacq, Delphine / Denning, Nicola / Jian, Xueqiu / Zhao, Yi / Del Zompo, Maria / Fox, Nick C / Choi, Seung-Hoan / Mateo, Ignacio / Hughes, Joseph T / Adams, Hieab H / Malamon, John / Sanchez-Garcia, Florentino / Patel, Yogen / Brody, Jennifer A / Dombroski, Beth A / Naranjo, Maria Candida Deniz / Daniilidou, Makrina / Eiriksdottir, Gudny / Mukherjee, Shubhabrata / Wallon, David / Uphill, James / Aspelund, Thor / Cantwell, Laura B / Garzia, Fabienne / Galimberti, Daniela / Hofer, Edith / Butkiewicz, Mariusz / Fin, Bertrand / Scarpini, Elio / Sarnowski, Chloe / Bush, Will S / Meslage, Stéphane / Kornhuber, Johannes / White, Charles C / Song, Yuenjoo / Barber, Robert C / Engelborghs, Sebastiaan / Sordon, Sabrina / Voijnovic, Dina / Adams, Perrie M / Vandenberghe, Rik / Mayhaus, Manuel / Cupples, L Adrienne / Albert, Marilyn S / De Deyn, Peter P / Gu, Wei / Himali, Jayanadra J / Beekly, Duane / Squassina, Alessio / Hartmann, Annette M / Orellana, Adelina / Blacker, Deborah / Rodriguez-Rodriguez, Eloy / Lovestone, Simon / Garcia, Melissa E / Doody, Rachelle S / Munoz-Fernadez, Carmen / Sussams, Rebecca / Lin, Honghuang / Fairchild, Thomas J / Benito, Yolanda A / Holmes, Clive / Karamujić-Čomić, Hata / Frosch, Matthew P / Thonberg, Hakan / Maier, Wolfgang / Roshchupkin, Gennady / Ghetti, Bernardino / Giedraitis, Vilmantas / Kawalia, Amit / Li, Shuo / Huebinger, Ryan M / Kilander, Lena / Moebus, Susanne / Hernández, Isabel / Kamboh, M Ilyas / Brundin, RoseMarie / Turton, James / Yang, Qiong / Katz, Mindy J / Concari, Letizia / Lord, Jenny / Beiser, Alexa S / Keene, C Dirk / Helisalmi, Seppo / Kloszewska, Iwona / Kukull, Walter A / Koivisto, Anne Maria / Lynch, Aoibhinn / Tarraga, Lluís / Larson, Eric B / Haapasalo, Annakaisa / Lawlor, Brian / Mosley, Thomas H / Lipton, Richard B / Solfrizzi, Vincenzo / Gill, Michael / Longstreth, W T / Montine, Thomas J / Frisardi, Vincenza / Diez-Fairen, Monica / Rivadeneira, Fernando / Petersen, Ronald C / Deramecourt, Vincent / Alvarez, Ignacio / Salani, Francesca / Ciaramella, Antonio / Boerwinkle, Eric / Reiman, Eric M / Fievet, Nathalie / Rotter, Jerome I / Reisch, Joan S / Hanon, Olivier / Cupidi, Chiara / Andre Uitterlinden, A G / Royall, Donald R / Dufouil, Carole / Maletta, Raffaele Giovanni / de Rojas, Itziar / Sano, Mary / Brice, Alexis / Cecchetti, Roberta / George-Hyslop, Peter St / Ritchie, Karen / Tsolaki, Magda / Tsuang, Debby W / Dubois, Bruno / Craig, David / Wu, Chuang-Kuo / Soininen, Hilkka / Avramidou, Despoina / Albin, Roger L / Fratiglioni, Laura / Germanou, Antonia / Apostolova, Liana G / Keller, Lina / Koutroumani, Maria / Arnold, Steven E / Panza, Francesco / Gkatzima, Olymbia / Asthana, Sanjay / Hannequin, Didier / Whitehead, Patrice / Atwood, Craig S / Caffarra, Paolo / Hampel, Harald / Quintela, Inés / Carracedo, Ángel / Lannfelt, Lars / Rubinsztein, David C / Barnes, Lisa L / Pasquier, Florence / Frölich, Lutz / Barral, Sandra / McGuinness, Bernadette / Beach, Thomas G / Johnston, Janet A / Becker, James T / Passmore, Peter / Bigio, Eileen H / Schott, Jonathan M / Bird, Thomas D / Warren, Jason D / Boeve, Bradley F / Lupton, Michelle K / Bowen, James D / Proitsi, Petra / Boxer, Adam / Powell, John F / Burke, James R / Kauwe, John S K / Burns, Jeffrey M / Mancuso, Michelangelo / Buxbaum, Joseph D / Bonuccelli, Ubaldo / Cairns, Nigel J / McQuillin, Andrew / Cao, Chuanhai / Livingston, Gill / Carlson, Chris S / Bass, Nicholas J / Carlsson, Cynthia M / Hardy, John / Carney, Regina M / Bras, Jose / Carrasquillo, Minerva M / Guerreiro, Rita / Allen, Mariet / Chui, Helena C / Fisher, Elizabeth / Masullo, Carlo / Crocco, Elizabeth A / DeCarli, Charles / Bisceglio, Gina / Dick, Malcolm / Ma, Li / Duara, Ranjan / Graff-Radford, Neill R / Evans, Denis A / Hodges, Angela / Faber, Kelley M / Scherer, Martin / Fallon, Kenneth B / Riemenschneider, Matthias / Fardo, David W / Heun, Reinhard / Farlow, Martin R / Kölsch, Heike / Ferris, Steven / Leber, Markus / Foroud, Tatiana M / Heuser, Isabella / Galasko, Douglas R / Giegling, Ina / Gearing, Marla / Hüll, Michael / Geschwind, Daniel H / Gilbert, John R / Morris, John / Green, Robert C / Mayo, Kevin / Growdon, John H / Feulner, Thomas / Hamilton, Ronald L / Harrell, Lindy E / Drichel, Dmitriy / Honig, Lawrence S / Cushion, Thomas D / Huentelman, Matthew J / Hollingworth, Paul / Hulette, Christine M / Hyman, Bradley T / Marshall, Rachel / Jarvik, Gail P / Meggy, Alun / Abner, Erin / Menzies, Georgina E / Jin, Lee-Way / Leonenko, Ganna / Real, Luis M / Jun, Gyungah R / Baldwin, Clinton T / Grozeva, Detelina / Karydas, Anna / Russo, Giancarlo / Kaye, Jeffrey A / Kim, Ronald / Jessen, Frank / Kowall, Neil W / Vellas, Bruno / Kramer, Joel H / Vardy, Emma / LaFerla, Frank M / Jöckel, Karl-Heinz / Lah, James J / Dichgans, Martin / Leverenz, James B / Mann, David / Levey, Allan I / Pickering-Brown, Stuart / Lieberman, Andrew P / Klopp, Norman / Lunetta, Kathryn L / Wichmann, H-Erich / Lyketsos, Constantine G / Morgan, Kevin / Marson, Daniel C / Brown, Kristelle / Martiniuk, Frank / Medway, Christopher / Mash, Deborah C / Nöthen, Markus M / Masliah, Eliezer / Hooper, Nigel M / McCormick, Wayne C / Daniele, Antonio / McCurry, Susan M / Bayer, Anthony / McDavid, Andrew N / Gallacher, John / McKee, Ann C / van den Bussche, Hendrik / Mesulam, Marsel / Brayne, Carol / Miller, Bruce L / Riedel-Heller, Steffi / Miller, Carol A / Miller, Joshua W / Al-Chalabi, Ammar / Morris, John C / Shaw, Christopher E / Myers, Amanda J / Wiltfang, Jens / O'Bryant, Sid / Olichney, John M / Alvarez, Victoria / Parisi, Joseph E / Singleton, Andrew B / Paulson, Henry L / Collinge, John / Perry, William R / Mead, Simon / Peskind, Elaine / Cribbs, David H / Rossor, Martin / Pierce, Aimee / Ryan, Natalie S / Poon, Wayne W / Nacmias, Benedetta / Potter, Huntington / Sorbi, Sandro / Quinn, Joseph F / Sacchinelli, Eleonora / Raj, Ashok / Spalletta, Gianfranco / Raskind, Murray / Caltagirone, Carlo / Bossù, Paola / Orfei, Maria Donata / Reisberg, Barry / Clarke, Robert / Reitz, Christiane / Smith, A David / Ringman, John M / Warden, Donald / Roberson, Erik D / Wilcock, Gordon / Rogaeva, Ekaterina / Bruni, Amalia Cecilia / Rosen, Howard J / Gallo, Maura / Rosenberg, Roger N / Ben-Shlomo, Yoav / Sager, Mark A / Mecocci, Patrizia / Saykin, Andrew J / Pastor, Pau / Cuccaro, Michael L / Vance, Jeffery M / Schneider, Julie A / Schneider, Lori S / Slifer, Susan / Seeley, William W / Smith, Amanda G / Sonnen, Joshua A / Spina, Salvatore / Stern, Robert A / Swerdlow, Russell H / Tang, Mitchell / Tanzi, Rudolph E / Trojanowski, John Q / Troncoso, Juan C / Van Deerlin, Vivianna M / Van Eldik, Linda J / Vinters, Harry V / Vonsattel, Jean Paul / Weintraub, Sandra / Welsh-Bohmer, Kathleen A / Wilhelmsen, Kirk C / Williamson, Jennifer / Wingo, Thomas S / Woltjer, Randall L / Wright, Clinton B / Yu, Chang-En / Yu, Lei / Saba, Yasaman / Pilotto, Alberto / Bullido, Maria J / Peters, Oliver / Crane, Paul K / Bennett, David / Bosco, Paola / Coto, Eliecer / Boccardi, Virginia / De Jager, Phil L / Lleo, Alberto / Warner, Nick / Lopez, Oscar L / Ingelsson, Martin / Deloukas, Panagiotis / Cruchaga, Carlos / Graff, Caroline / Gwilliam, Rhian / Fornage, Myriam / Goate, Alison M / Sanchez-Juan, Pascual / Kehoe, Patrick G / Amin, Najaf / Ertekin-Taner, Nilifur / Berr, Claudine / Debette, Stéphanie / Love, Seth / Launer, Lenore J / Younkin, Steven G / Dartigues, Jean-Francois / Corcoran, Chris / Ikram, M Arfan / Dickson, Dennis W / Nicolas, Gael / Campion, Dominique / Tschanz, JoAnn / Schmidt, Helena / Hakonarson, Hakon / Clarimon, Jordi / Munger, Ron / Schmidt, Reinhold / Farrer, Lindsay A / Van Broeckhoven, Christine / C O'Donovan, Michael / DeStefano, Anita L / Jones, Lesley / Haines, Jonathan L / Deleuze, Jean-Francois / Owen, Michael J / Gudnason, Vilmundur / Mayeux, Richard / Escott-Price, Valentina / Psaty, Bruce M / Ramirez, Alfredo / Wang, Li-San / Ruiz, Agustin / van Duijn, Cornelia M / Holmans, Peter A / Seshadri, Sudha / Williams, Julie / Amouyel, Phillippe / Schellenberg, Gerard D / Lambert, Jean-Charles / Pericak-Vance, Margaret A

    Nature genetics

    2019  Volume 51, Issue 3, Page(s) 414–430

    Abstract: Risk for late-onset Alzheimer's disease (LOAD), the most prevalent dementia, is partially driven by genetics. To identify LOAD risk loci, we performed a large genome-wide association meta-analysis of clinically diagnosed LOAD (94,437 individuals). We ... ...

    Abstract Risk for late-onset Alzheimer's disease (LOAD), the most prevalent dementia, is partially driven by genetics. To identify LOAD risk loci, we performed a large genome-wide association meta-analysis of clinically diagnosed LOAD (94,437 individuals). We confirm 20 previous LOAD risk loci and identify five new genome-wide loci (IQCK, ACE, ADAM10, ADAMTS1, and WWOX), two of which (ADAM10, ACE) were identified in a recent genome-wide association (GWAS)-by-familial-proxy of Alzheimer's or dementia. Fine-mapping of the human leukocyte antigen (HLA) region confirms the neurological and immune-mediated disease haplotype HLA-DR15 as a risk factor for LOAD. Pathway analysis implicates immunity, lipid metabolism, tau binding proteins, and amyloid precursor protein (APP) metabolism, showing that genetic variants affecting APP and Aβ processing are associated not only with early-onset autosomal dominant Alzheimer's disease but also with LOAD. Analyses of risk genes and pathways show enrichment for rare variants (P = 1.32 × 10
    MeSH term(s) Aged ; Alzheimer Disease/genetics ; Amyloid beta-Peptides/genetics ; Case-Control Studies ; Female ; Genetic Loci/genetics ; Genetic Predisposition to Disease/genetics ; Genetic Testing/methods ; Genome-Wide Association Study/methods ; Haplotypes/genetics ; Humans ; Immunity/genetics ; Lipid Metabolism/genetics ; Lipids/genetics ; Male ; tau Proteins/genetics
    Chemical Substances Amyloid beta-Peptides ; Lipids ; tau Proteins
    Language English
    Publishing date 2019-02-28
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't
    ZDB-ID 1108734-1
    ISSN 1546-1718 ; 1061-4036
    ISSN (online) 1546-1718
    ISSN 1061-4036
    DOI 10.1038/s41588-019-0358-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top